1. "2022"
Formats
  1. Journal Article (2449)
  2. Meeting Abstract (2196)
  3. Review (615)
  4. Editorial (363)
  5. Book Section (139)
  6. Correspondence (117)
  7. Guidelines (112)
  8. Research Letter (82)
  9. Miscellaneous (60)
  10. Conference Paper (29)
  11. Book Whole (6)
Groups
  1. Department of Medicine (2621)
  2. Solid Tumor Oncology Division (1573)
  3. Sloan Kettering Institute Postdocs (1364)
  4. GSK Faculty (1152)
  5. Surgery (1036)
  6. Hematologic Malignancies, Division of (964)

More Groups

People
  1. Miguel-Angel Perales (95)
  2. Alexander Drilon (85)
  3. Saad Usmani (83)
  4. Sergio Giralt (77)
  5. Marc Ladanyi (72)
  6. Gilles Salles (69)

More People

Years
  1. 2022 (6168)
Publications
  1. Journal of Clinical Oncology (520)
  2. Blood (319)
  3. Cancer Research (191)
  4. Annals of Oncology (158)
  5. Annals of Surgical Oncology (134)
  6. International Journal of Radiation Oncology, Biology, Physics (132)

More Publications

Publishers
  1. Elsevier Inc. (794)
  2. American Society of Clinical Oncology (583)
  3. Springer (440)
  4. Nature Publishing Group (379)
  5. American Society of Hematology (369)
  6. Oxford University Press (360)

More Publishers

Results (6168)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)
    Meeting Abstract

    Migden, M. R.; Luke, J. J.; Chai-Ho, W.; Kheterpal, M.; Wise-Draper, T. M.; Poklepovic, A. S.; Bolotin, D.; Verschraegen, C. F.; Collichio, F. A.; Tang, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors
    Meeting Abstract

    Meric-Bernstam, F.; Sharma, M.; Sommerhalder, D.; Skeel, R. T.; El-Khoueiry, A. B.; Caswell-Jin, J. L.; Patel, P. H.; Rosen, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer
    Meeting Abstract

    McArthur, H. L.; Comen, E. A.; Bryce, Y.; Solomon, S. B.; Leal, J. H. S.; Abaya, C. D.; Martinez, C.; Basho, R. K.; Park, D. J.; McAndrew, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma
    Meeting Abstract

    McKean, M.; Aggen, D. H.; Lakhani, N. J.; Bashir, B.; Luke, J. J.; Hoffman-Censits, J. H.; Alhalabi, O.; Bowman, I. A.; Guancial, E. A.; Tan, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors
    Meeting Abstract

    McKean, M.; Tolcher, A. W.; Reeves, J. A.; Chmielowski, B.; Shaheen, M. F.; Beck, J. T.; Orloff, M. M.; Somaiah, N.; Van Tine, B. A.; Drabick, J. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P)
    Meeting Abstract

    McConkey, D. J.; Choi, W.; Halabi, S.; Luo, B.; Al-Ahmadie, H. A.; Rosenberg, J. E.; Mountain, J.; Regazzi, A. M.; Fong, M.; Iyer, G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Matasar, M. J.; Haioun, C.; Sancho, J. M.; Viardot, A.; Izquierdo, A. R.; Martin, E. M. D.; Garcia-Sancho, A. M.; Sandoval-Sus, J. D.; Tilly, H.; Vandenberghe, E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician's choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K. Q.; Londhe, A.; Nair, S.; Lin, X. W.; Pei, L. X.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Utility of liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in lymphomas and plasma cell neoplasms
    Meeting Abstract

    Mata, D. A.; Shanmugam, V.; Decker, B. J.; Schrock, A. B.; Tukachinsky, H.; Williams, E. A.; Ross, J. S.; Montesion, M.; Oxnard, G. R.; Vergilio, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies
    Meeting Abstract

    Mato, A.; Danilov, A. V.; Patel, M. R.; Tees, M. T.; Flinn, I. W.; Ai, W. Z.; Patel, K.; Wang, M.; O'Brien, S. M.; Nandakumar, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save